Products Under Development

As of July 30, 2026

Pharmaceuticals

Products Under Development: Pharmaceuticals
Code Proposed Indication Stage Origin Features
Japan Overseas
KRP-114VP Overactive bladder (for pediatric patients) Ph3 — Merck
  • β3-adrenergic receptor agonist
  • Enhances bladder relaxation during storage phase to increase capacity and improve OAB symptoms (urgency, frequency, and UUI)
KRP-S124 OSA etc. Ph1
Bayer		 Bayer
  • ADRA2C antagonist
  • Centrally reduces upper airway collapse, with expected improvements in transient apnea and hypopnea
KRP-A225 Systemic Lupus Erythematosus (SLE), etc. Ph1
Hinge Bio		 Hinge Bio
  • A bispecific antibody targeting CD19 and CD20 on the surface of B cells
  • "Reset" the immune system through B cell depletion
KRP-126 Neuropathic Pain Ph1
BIODOL		 BIODOL Therapeutics
  • FLT3 Negative allosteric modulator
  • Exerts a negative modulatory effect on FLT3, a key driver of chronic pain onset and persistence, offering strong analgesic effects

Digital Therapeutics, DTx

Products Under Development: Digital Therapeutics, DTx
Code Proposed Indication Stage Partner Features
KRP-DT123 Tinnitus Confirmatory Study SUSUMED
  • DTx for Tunnitus
KRP-DC125 Chronic Cough Confirmatory Study Hyfe
  • DTx for Chronic Chough

Licensing development (License-out)

Products Under Development: Licensing development (License-out)
Code Proposed Indication Stage Licensee Origin Features
KRP-M223 Allergic and inflammatory diseases involving mast cells, such CSU etc. Pre-clinical Novartis In-house
  • MRGPRX2 antagonist